7 research outputs found
Π Π΅Π°Π»ΠΈΠ·Π°ΡΠΈΡ POMDP-ΠΌΠΎΠ΄Π΅Π»ΠΈ Honeypot ΡΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ Π² ΠΏΠ°ΠΊΠ΅ΡΠ΅ R
Markov decision process and its extensions are used to solve a variety of applied problems related to the problem of making an optimal decision, including under conditions of uncertainty. For example, a Partially Observable Markov Decision Process is used to solve robot navigation problems. Honeypot technology is an imitation of a real system, and is used to collect various types of information about attackers who compromise it. The framework described above can be applied to model a Honeypot system, which allows the system to solve the problem of determining its state and choosing the optimal action. This paper discusses a high interaction Honeypot model based on a Partially Observable Markov Decision Process, as well as the results of its implementation using the tools of the R package. Using the pomdp library, sets of states, actions, and observations have been described, as well as a transition function, a reward function, and an observation function. And also the optimal policy was found and analyzed for one set of system parameters.ΠΠ°ΡΠΊΠΎΠ²ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΡΠΈΠ½ΡΡΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΈ Π΅Π³ΠΎ ΡΠ°ΡΡΠΈΡΠ΅Π½ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡΡΡ Π΄Π»Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·Π½ΡΡ
ΠΏΡΠΈΠΊΠ»Π°Π΄Π½ΡΡ
Π·Π°Π΄Π°Ρ, ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ ΠΏΡΠΈΠ½ΡΡΠΈΡ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
Π½Π΅ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ½Π½ΠΎΡΡΠΈ. ΠΠ°ΠΏΡΠΈΠΌΠ΅Ρ, ΡΠ°ΡΡΠΈΡΠ½ΠΎ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΠΉ ΠΠ°ΡΠΊΠΎΠ²ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΡΠΈΠ½ΡΡΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΡΡΡ Π΄Π»Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌ Π½Π°Π²ΠΈΠ³Π°ΡΠΈΠΈ ΡΠΎΠ±ΠΎΡΠΎΠ². Π’Π΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡ Honeypot ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ ΠΈΠΌΠΈΡΠ°ΡΠΈΡ ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ Π΄Π»Ρ ΡΠ±ΠΎΡΠ° ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ΄Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΎ Π·Π»ΠΎΡΠΌΡΡΠ»Π΅Π½Π½ΠΈΠΊΠ°Ρ
, ΠΊΠΎΡΠΎΡΡΠ΅ Π΅Ρ ΠΊΠΎΠΌΠΏΡΠΎΠΌΠ΅ΡΠΈΡΡΡΡ. ΠΠΏΠΈΡΠ°Π½Π½ΡΠΉ Π²ΡΡΠ΅ Π°ΠΏΠΏΠ°ΡΠ°Ρ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ½ Π΄Π»Ρ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΡ Honeypot, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠΈΡΡΠ΅ΠΌΠ΅ ΡΠ΅ΡΠΈΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠ²ΠΎΠ΅Π³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΈ Π²ΡΠ±ΠΎΡΠ° ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ. Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ ΠΌΠΎΠ΄Π΅Π»Ρ Honeypot ΡΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠ°ΡΡΠΈΡΠ½ΠΎ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΠΎΠ³ΠΎ ΠΠ°ΡΠΊΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΏΡΠΈΠ½ΡΡΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΅Ρ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΡΡΠ΅Π΄ΡΡΠ² ΠΏΠ°ΠΊΠ΅ΡΠ° R. Π‘ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊΠΈ pomdp Π±ΡΠ»ΠΈ ΠΎΠΏΠΈΡΠ°Π½Ρ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΡ, ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ
Π΄Π΅ΠΉΡΡΠ²ΠΈΠΉ ΠΈ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ, ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Ρ
ΠΎΠ΄Π° ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΡΡΠΎΡΠ½ΠΈΡΠΌΠΈ, Π²ΠΎΠ·Π½Π°Π³ΡΠ°ΠΆΠ΄Π΅Π½ΠΈΡ ΠΈ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ. Π ΡΠ°ΠΊΠΆΠ΅ Π±ΡΠ»Π° Π½Π°ΠΉΠ΄Π΅Π½Π° ΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π° ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½Π°Ρ ΠΏΠΎΠ»ΠΈΡΠΈΠΊΠ° Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ Π½Π°Π±ΠΎΡΠ° ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΡΠΈΡΡΠ΅ΠΌΡ
New chromophores based on combination of ethylenedioxythiophene and carbazole fragments: synthesis and optoelectronic properties
Two new D-Ο-A chromophores composed of
an electron-donating carbazole unit linked through Ο-
bridges, bearing 3,4-ethylenedioxythiophene (EDOT) moiety,
with an electron withdrawing dicyanovinyl group
(DCV) were successfully synthesized involving Suzuki or
Heck cross-coupling and KnΓΆevenagel reactions as the
key steps. The obtained compounds absorb light over
a broad spectral range, including the visible spectrum.
The HOMO/LUMO energies and band gap energy values
(Eg) were calculated on the basis of the experimental
optical and electrochemical data: HOMO, LUMO, Eg
(eV), β5.51, β3.14, 2.37 (4), β5.34, β3.14, 2.20 (7). The
presence of the HC=CH unit in compound 7 resulted in
the increase of the HOMO energy level, the decrease of
a band gap value and red shifts of the absorption and
emission bands in comparison with those of 4. Large
Stokes shifts and broadband luminescence inherent to
both chromophores suggest their use as materials for luminescent
solar collectors (LSCs). The obtained compounds
demonstrated good solubility and suitable thin-film forming
properties. For this reason, they may be suitable for
solution-processable photovoltaic applications
Effect of Systemic Polyelectrolyte Microcapsule Administration on the Blood Flow Dynamics of Vital Organs
Polyelectrolyte microcapsules and other targeted drug delivery systems could substantially reduce the side effects of drug and overall toxicity. At the same time, the cardiovascular system is a unique transport avenue that can deliver drug carriers to any tissue and organ. However, one of the most important potential problems of drug carrier systemic administration in clinical practice is that the carriers might cause circulatory disorders, the development of pulmonary embolism, ischemia, and tissue necrosis due to the blockage of small capillaries. Thus, the presented work aims to find out the processes occurring in the bloodstream after the systemic injection of polyelectrolyte capsules that are 5 ΞΌm in size. It was shown that 1 min after injection, the number of circulating capsules decreases several times, and after 15 min less than 1% of the injected dose is registered in the blood. By this time, most capsules accumulate in the lungs, liver, and kidneys. However, magnetic field action could slightly increase the accumulation of capsules in the region-of-interest. For the first time, we have investigated the real-time blood flow changes in vital organs in vivo after intravenous injection of microcapsules using a laser speckle contrast imaging system. We have demonstrated that the organism can adapt to the emergence of drug carriers in the blood and their accumulation in the vessels of vital organs. Additionally, we have evaluated the safety of the intravenous administration of various doses of microcapsules. Β© 2019 American Chemical Society
ΠΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ ΡΠ°Π±ΠΎΡΠΈΡ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² ΠΏΠΎ ΡΠ΅ΠΊΡΡΡΠΈΠ½Π³Ρ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅ ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ COVID-19
Background. The pandemic of the new coronavirus infection has challenged the medical community for quickly finding and implementing effective methods of treatment. In the absence of a vaccine or specific therapy with proven effectiveness, the usage of convalescent plasma can be the one of perspective methods. An important aspect of this technology is the efficient and safe preparation of convalescent plasma. To date, in the world literature there are practically no publications about donor recruitment and the specifics of the preparation of convalescent plasma.
Purpose of the research. Presentation of the experience of organizing a workflow for recruiting donors and stockpiling of convalescent plasma with a high titer of virus-neutralizing antibodies to SARS-CoV-2.
Methods. The analysis of the work of the Blood Service of the Moscow Department of Health for stockpiling of COVID-19 convalescent plasma has been executed. In total it has been stockpiled 1240 doses. The normative documentation has been developed by a working group on the basis of the current federal legislation of Russian federation and been approved by the Moscow Department of Health. The titer of neutralizing antibodies (VNA) has been determined as the basic method for assessing the immunological viability of convalescent plasma. The main characteristics of donors, the characteristics of the disease course, the results of preliminary testing for the presence of specific antibodies by ELISA and CLIA methods has been compared with VNA titers in the stockpiled convalescent plasma.
Results. Due to a Moscow Health Departments order No. 325 dated 01.04.2020 (a basic local regulatory document) it has been developed a regulation for the stockpiling, examination, storage, safety and transfering of fresh frozen pathogen-reduced plasma of COVID-19 convalescent donors to medical organizations of the Moscow Health Department. For arranging an interaction with donors it has been created a call-center. For effective preliminary selection, it has been formed a donor characteristics list, which has been combined with screening of specific antibodies by ELISA and CLIA methods.
Conclusions. Developed a system of recruiting donors and procurement process of convalescent plasma for treatment Π‘OVID-19, which includes the necessary regulations, algorithms for the selection and recruitment of donors, the registry of donors and recipients, algorithms, efficiency and safety of convalescent plasma.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΠ°Π½Π΄Π΅ΠΌΠΈΡ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΠΎΡΡΠ°Π²ΠΈΠ»Π° ΠΏΠ΅ΡΠ΅Π΄ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠΌ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²ΠΎΠΌ Π·Π°Π΄Π°ΡΡ Π±ΡΡΡΡΠΎΠ³ΠΎ ΠΏΠΎΠΈΡΠΊΠ° ΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ. Π ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΎΡΡΡΡΡΡΠ²ΠΈΡ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΈ ΡΡΠ΅Π΄ΡΡΠ² ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ ΡΡΠ°Π½ΡΡΡΠ·ΠΈΡ ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΡ (Π Π). ΠΠ°ΠΆΠ½ΡΠΌ Π°ΡΠΏΠ΅ΠΊΡΠΎΠΌ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°. ΠΠ° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΈ ΠΏΠΎ ΡΠ΅ΠΊΡΡΡΠΈΠ½Π³Ρ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠΈ Π Π Π² ΠΌΠΈΡΠΎΠ²ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΡΡΡΡΡΡΠ²ΡΡΡ.
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΠ½Π°Π»ΠΈΠ· ΠΎΠΏΡΡΠ° ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΡΠ°Π±ΠΎΡΠ΅Π³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΏΠΎ ΠΏΡΠΈΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅ Π Π Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΠΈΡΡΠΎΠΌ Π²ΠΈΡΡΡΠ½Π΅ΠΉΡΡΠ°Π»ΠΈΠ·ΡΡΡΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΊ SARS-CoV-2.
ΠΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΡΠ°Π±ΠΎΡΡ Π‘Π»ΡΠΆΠ±Ρ ΠΊΡΠΎΠ²ΠΈ ΠΠ΅ΠΏΠ°ΡΡΠ°ΠΌΠ΅Π½ΡΠ° Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ Π³. ΠΠΎΡΠΊΠ²Ρ (ΠΠΠ) ΠΏΠΎ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅ Π Π COVID-19. ΠΡΠ΅Π³ΠΎ Π·Π°Π³ΠΎΡΠΎΠ²Π»Π΅Π½ΠΎ 1240 Π΄ΠΎΠ·. ΠΠΎΡΠΌΠ°ΡΠΈΠ²Π½Π°Ρ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠ°Π±ΠΎΡΠ΅ΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π·Π°ΠΊΠΎΠ½ΠΎΠ΄Π°ΡΠ΅Π»ΡΡΡΠ²Π° ΠΈ ΡΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π° ΠΠΠ. ΠΠ°ΠΊ Π±Π°Π·ΠΎΠ²Π°Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π Π, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ ΡΠΈΡΡ Π²ΠΈΡΡΡΠ½Π΅ΠΉΡΡΠ°Π»ΠΈΠ·ΡΡΡΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» (ΠΠΠ). ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π΄ΠΎΠ½ΠΎΡΠΎΠ², ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π° Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΠ€Π ΠΈ ΠΠ₯ΠΠ Ρ ΡΠΈΡΡΠ°ΠΌΠΈ ΠΠΠ Π·Π°Π³ΠΎΡΠΎΠ²Π»Π΅Π½Π½ΠΎΠΉ Π Π.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π°Π±ΠΎΡΠ° ΠΏΠΎ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅, ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, Ρ
ΡΠ°Π½Π΅Π½ΠΈΡ, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π΄Π°ΡΠ΅ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠ΅ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΠΠ ΡΠ²Π΅ΠΆΠ΅Π·Π°ΠΌΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ³Π΅Π½ΡΠ΅Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ²-ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠΎΠ² COVID-19 Π±ΡΠ»Π° ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΎΠ²Π°Π½Π° Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠΊΠ°Π·Π° ΠΠΠ ΠΎΡ 01.04.2020 β 325 ΠΊΠ°ΠΊ Π±Π°Π·ΠΎΠ²ΠΎΠ³ΠΎ Π»ΠΎΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°. ΠΠ»Ρ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΈ Ρ ΡΠΎΡΡΠΎΡΠ²ΡΠΈΠΌΠΈΡΡ Π΄ΠΎΠ½ΠΎΡΠ°ΠΌΠΈ ΠΈ ΠΏΡΠΈΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΡΠ΅ΡΡΡΡΡ ΠΊΠΎΠ»Π»-ΡΠ΅Π½ΡΡΠ°. ΠΠ»Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠ±ΠΎΡΠ° Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈΡΡ Π°Π½Π°Π»ΠΈΠ· Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π΄ΠΎΠ½ΠΎΡΠ° (ΠΏΠ»Π°Π·ΠΌΠ° Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΌΠΈ Π·Π½Π°ΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠΈΡΡΠ° ΠΠΠ ΠΎΠΆΠΈΠ΄Π°Π΅ΠΌΠ° ΠΎΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ²-ΠΌΡΠΆΡΠΈΠ½, ΠΏΠ΅ΡΠ΅Π±ΠΎΠ»Π΅Π²ΡΠΈΡ
Ρ ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ ΡΠ²Π½ΠΎΠΉ Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ) ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΠ€Π ΠΈ ΠΠ₯ΠΠ.
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ° ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΡΡΡΠΈΠ½Π³Π° Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠΈ Π Π Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π‘OVID-19, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ°Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΠ΅ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΠ΅ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΡ, Π°Π»Π³ΠΎΡΠΈΡΠΌΡ ΠΎΡΠ±ΠΎΡΠ° ΠΈ ΠΏΡΠΈΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ², ΡΠ΅Π΅ΡΡΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², Π°Π»Π³ΠΎΡΠΈΡΠΌΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π Π